Last update: February 2019
Sanofi has additional clinical trials for Praluent including:
ODYSSEY DM-Insulin [NCT02585778]1
A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Praluent in insulin treated patients with type 1 or type 2 diabetes and with hypercholesterolemia at high cardiovascular risk not adequately controlled on maximally tolerated LDL-C lowering therapy.
For more information please see clinicaltrials.gov.
ODYSSEY DM -Dyslipidaemia [NCT02642159]2
A randomized, open-label, parallel group study to evaluate the efficacy and safety of Praluent versus usual care in patients with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk with non-HDL-C not adequately controlled with maximally tolerated statin therapy.
For more information on these trials and other trials involving Praluent please see clinicaltrials.gov.
- ClinicalTrials.gov NCT02585778. Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin).
- ClinicalTrials.gov NCT02642159. Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)